Ann McCoy

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer”.

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add7872

N/A

0.790DataRank · unranked

25 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2530

N/A

0.165DataRank · unranked

2 citations

Massimo Fantini, Kwong Y. Tsang, Kevin C. Conlon, Charalampos S. Floudas, Azam Ghafoor +8 more

A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Cancer Medicine(2025)10.1002/cam4.71220

N/A

0.104DataRank · unranked

1 citations

Ashley Cimino‐Mathews, Stanley Lipkowitz, Min-Jung Lee, Jayakumar R. Nair, B. Brooke Solarz +9 more

Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6038

N/A

0DataRank · unranked

7 citations

Daniel An, Ann McCoy, Elise C. Kohn, Christina M. Annunziata, Kathryn Trewhitt +4 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6

N/A

0DataRank · unranked

42 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14515

N/A

0DataRank · unranked

0 citations

Christopher B. Cole, Ann McCoy, Massimo Fantini, Sharon Mavroukakis, Anjum Zaki +4 more

Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1893

N/A

0DataRank · unranked

21 citations

Franklin Ning, Anna Duemler, Timothy G. Myers, Kathryn Trewhitt, Irene Ekwede +24 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

medRxiv(2022)10.1101/2022.12.02.22283037

N/A

0DataRank · unranked

2 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more